Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective lifted by equities researchers at Guggenheim from $110.00 to $125.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s target price points to a potential upside of 54.02% from the stock’s […]
UBS Group began coverage on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research note published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $111.00 price target on the stock. AXSM has been the subject of a number of other research reports. Royal Bank of Canada assumed coverage on […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $95.00 and last traded at $94.95, with a volume of 237699 shares traded. The stock had previously closed at $91.50. Analyst Upgrades and Downgrades Several research firms recently […]
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) – Equities researchers at Leerink Partnrs raised their FY2023 earnings per share estimates for Axsome Therapeutics in a research note issued on Monday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of ($4.07) for the year, up from their […]